Leqembi — Competitive Intelligence Brief

Leqembi (LECANEMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amyloid Beta-directed Antibody [EPC]. Area: Immunology.

marketed Amyloid Beta-directed Antibody [EPC] Amyloid beta A4 protein Immunology Monoclonal antibody

Target snapshot

Leqembi (LECANEMAB) — Eisai. Leqembi works by binding to and removing amyloid beta A4 protein from the brain, which is thought to contribute to the progression of Alzheimer's disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Leqembi TARGET	LECANEMAB	Eisai	marketed	Amyloid Beta-directed Antibody [EPC]	Amyloid beta A4 protein	2023-01-01
Aduhelm	ADUCANUMAB	Biogen	marketed	Amyloid Beta-directed Antibody	Amyloid beta A4 protein	2021-01-01
Neuraceq	FLORBETABEN F18	Piramal Imaging	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2014-01-01
Vizamyl	Flutemetamol (18F)	GE HealthCare	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2013-01-01
Amyvid	FLORBETAPIR F 18	Avid Radiopharms Inc	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2012-01-01
Calcium Disodium Versenate	EDETIC ACID	Medicis	marketed	Anti-coagulant	Amyloid beta A4 protein	1953-01-01
M.V.I. Pediatric	RETINOL	Pfizer	marketed	Vitamin A	Amyloid beta A4 protein	1953-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2027-04-30 — Amyvid · 8506929 · US
• 2027-04-30 — Amyvid · 7687052 · US
• 2028-09-16 — Vizamyl · 8916131 · US
• 2029-03-18 — Neuraceq · 7807135 · US

Sponsor landscape (Amyloid Beta-directed Antibody [EPC] class)

1. EISAI INC · 1 drug in this class
2. Eisai · 1 drug in this class